A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer - Concepedia

Concepedia

Publication | Open Access

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

DOI Full Paper Access

27

Citations

15

References

2021

Year

Peter Schmid, Marie‐Paule Sablin, Jonas Bergh, Seock‐Ah Im, Yen‐Shen Lu, Noelia Martínez-Jáñez, Patrick Neven, Keun Seok Lee, Serafín Morales, José Alejandro Pérez Fidalgo,

Breast Cancer Research

Abstract

ClinicalTrials.gov, NCT02123823 . Prospectively registered, 8 March 2013.

References

	Year	Citations

Page 1